Gongwin Biopharm Holdings Co (ROCO:6617) NonCurrent Deferred Liabilities: NT$0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6617 Gongwin Biopharm Holdings Co Ltd ROCO:6617
48 GF Score
Price NT$102.50
! 2 Warning Signs
View Full Analysis

What is Gongwin Biopharm Holdings Co NonCurrent Deferred Liabilities?

Gongwin Biopharm Holdings Co ROCO:6617 -2.84% 48 NonCurrent Deferred Liabilities is NT$0.00 Mil as of Mar. 2026. GuruFocus rates ROCO:6617 with a GF Score™ of 48/100. The stock has 2 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Gongwin Biopharm Holdings Co's non-current deferred liabilities for the quarter that ended in Mar. 2026 was NT$0.00 Mil.

Gongwin Biopharm Holdings Co NonCurrent Deferred Liabilities Related Terms

Gongwin Biopharm Holdings Co NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Gongwin Biopharm Holdings Co's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gongwin Biopharm Holdings Co NonCurrent Deferred Liabilities Chart

Gongwin Biopharm Holdings Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Gongwin Biopharm Holdings Co Quarterly Data
Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ROCO:6617
48GF Score
Gongwin Biopharm Holdings Co Ltd ROCO:6617
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of NT$0.00 Mil mean?
Gongwin Biopharm Holdings Co (ROCO:6617) has a NonCurrent Deferred Liabilities of NT$0.00 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Gongwin Biopharm Holdings Co and its competitors.
Is Gongwin Biopharm Holdings Co's NonCurrent Deferred Liabilities too high?
Gongwin Biopharm Holdings Co's current NonCurrent Deferred Liabilities is NT$0.00 Mil. Overall, Gongwin Biopharm Holdings Co has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Gongwin Biopharm Holdings Co's NonCurrent Deferred Liabilities compare to VRTX and REGN?
Gongwin Biopharm Holdings Co's NonCurrent Deferred Liabilities of NT$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Gongwin Biopharm Holdings Co and its competitors. Gongwin Biopharm Holdings Co's current NonCurrent Deferred Liabilities is NT$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gongwin Biopharm Holdings Co stock overvalued right now?
Gongwin Biopharm Holdings Co (ROCO:6617) has a current NonCurrent Deferred Liabilities of NT$0.00 Mil. The current NonCurrent Deferred Liabilities is NT$0.00 Mil. Gongwin Biopharm Holdings Co's overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Gongwin Biopharm Holdings Co (ROCO:6617), the current NonCurrent Deferred Liabilities is NT$0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Gongwin Biopharm Holdings Co Business Description

Address 3rd Floor, No.80, Jianguo North Road, Section 1, Zongshan District, Taipei, TWN, 10491
Gongwin Biopharm Holdings Co Ltd is a Taiwan-based biopharmaceutical company focused on developing novel anti-cancer drugs. The company develops products related to central lung serious tracheal obstruction, primary liver cancer, malignant pleural effusion, and tracheal adenoid cystic carcinoma. The Group includes pharmaceutical research and development, drug testing, pharmaceutical technology consulting, biotechnology services, technology transfer, and the sale of new drugs.
48GF Score

Get the complete analysis for ROCO:6617

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$102.50
Price